Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:1358-1365
Published online before print September 8, 2008, doi: 10.1161/CIRCULATIONAHA.107.735985
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Circulation: September 23, 2008, Volume 118, Number 13
Right arrow Correction
Right arrow Correction (v118,pe670)
Right arrow All Versions of this Article:
118/13/1358    most recent
CIRCULATIONAHA.107.735985v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werk, M.
Right arrow Articles by Ricke, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werk, M.
Right arrow Articles by Ricke, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Angioplasty
*Peripheral Arterial Disease
Hazardous Substances DB
*TAXOL
Related Collections
Right arrow Restenosis
Right arrow Restenosis
Right arrow Peripheral vascular disease
Right arrow Other Treatment
Right arrowRelated Article

(Circulation. 2008;118:1358-1365.)
© 2008 American Heart Association, Inc.


Vascular Medicine

Inhibition of Restenosis in Femoropopliteal Arteries

Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial

Michael Werk, MD; Soenke Langner, MD; Bianka Reinkensmeier, MS; Hans-Frank Boettcher, MD; Gunnar Tepe, MD; Ulrich Dietz, MD; Norbert Hosten, MD; Bernd Hamm, MD; Ulrich Speck, PhD; Jens Ricke, MD

From Charité, Universitätsmedizin Berlin, Berlin (M.W., B.R., H.-F.B., B.H., U.S.); Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität, Greifswald (S.L., N.H.); Radiologische Klinik Universitätsklinikum Tübingen, Tübingen (G.T.); Deutsche Klinik für Diagnostik, Kardiologie, Wiesbaden (U.D.); and Klinik für Radiologie und Nuklearmedizin der Otto-von-Guericke-Universität Magdeburg, Magdeburg (J.R.), Germany.

Correspondence to Michael Werk, MD, Charité, Universitätsmedizin Berlin, Martin-Luther-Krankenhaus, Department of Radiology, Caspar-Theyß-Str 27–31, 14193 Berlin, Germany. E-mail m.werk{at}mlk-berlin.de

Received August 23, 2007; accepted June 10, 2008.

Background— The success of percutaneous intervention in peripheral arterial disease is limited by restenosis. The aim of the present pilot study was to evaluate a novel method of local drug delivery.

Methods and Results— This randomized multicenter study with blinded reading enrolled 87 patients in Rutherford class 1 to 4 with occlusion or hemodynamically relevant stenosis, restenosis, or in-stent restenosis of femoropopliteal arteries. Treatment was performed by either conventional uncoated or paclitaxel-coated balloon catheters. The primary end point was late lumen loss at 6 months. Secondary end points included restenosis rate, ankle brachial index, Rutherford class, target lesion revascularization, and tolerance up to >18 months. Before intervention, there were no significant differences in lesion characteristics such as reference diameter (5.3±1.1 versus 5.2±1.0 mm), degree of stenosis (84±11% versus 84±16%), proportion of restenotic lesions (36% versus 33%), and mean lesion length (5.7 cm [0.8 to 22.6 cm] versus 6.1 cm [0.9 to 19.3 cm]) between treatment groups. The 6-month follow-up angiography performed in 31 of 45 and 34 of 42 patients showed less late lumen loss in the coated balloon group (0.5±1.1 versus 1.0±1.1 mm; P=0.031). The number of target lesion revascularizations was lower in the paclitaxel-coated balloon group than in control subjects (3 of 45 versus 14 of 42 patients; P=0.002). Improvement in Rutherford class was greater in the coated balloon group (P=0.045), whereas the improvement in ankle brachial index was not different. The difference in target lesion revascularizations between treatment groups was maintained up to >18 months. No adverse events were assessed as related to balloon coating.

Conclusions— In this pilot trial, paclitaxel balloon coating caused no obvious adverse events and reduced restenosis in patients undergoing angioplasty of femoropopliteal arteries.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 118: 1307-1308. [Extract] [Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
M. Unverdorben, C. Vallbracht, B. Cremers, H. Heuer, C. Hengstenberg, C. Maikowski, G. S. Werner, D. Antoni, F. X. Kleber, W. Bocksch, et al.
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Circulation, June 16, 2009; 119(23): 2986 - 2994.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097.
[Full Text] [PDF]